# A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06117566/  
OnCo record `nct06117566` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Shanghai Jiatan Pharmatech Co., Ltd, now recruiting.

## Summary

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06117566 by Shanghai Jiatan Pharmatech Co., Ltd, with 100 participants planned, started 2022-11-18 and due to reach its primary completion in 2025-11-09. Interventions recorded: WX390 and Toripalimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06117566
- Phase: 1/2
- Setting: A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
- Sponsor: Shanghai Jiatan Pharmatech Co., Ltd
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06117566: https://clinicaltrials.gov/study/NCT06117566

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06117566.json